Advertisement

Picture [iito] Männer Ballett 650x80px
Document › Details

Targovax AS. (6/11/15). "Press Release: Targovax and Oncos Therapeutics Join Forces to Create a Nordic Leader within Immuno-oncology and Contemplate a Private Placement of NOK 125–150 Million to Fund the Combined Business [Not for US, AU, CA, JP]". Londo

Organisations Organisation Targovax ASA (OSE: TRVX)
  Organisation 2 Oncos Therapeutics Oy
  Group Polaris (NO) (Group)
Products Product cancer immunotherapy (immuno-oncology, I-O)
  Product 2 venture capital
Index terms Index term Oncos Therapeutics–Targovax: investment, 201506– merger 50/50 in shares ANNOUNCED to become Polaris
  Index term 2 Targovax–SEVERAL: investment, 201506– private placement to raise NOK125–150m + support merger w Oncos Therapeutics
Persons Person Gårdemyr, Gunnar (Follicum 201902 before Targovax/Polaris + Nycomed/Takeda)
  Person 2 Øystein, Soug (Polaris 201506 announced as CFO before Algeta + Orcla)
     


   
Record changed: 2016-01-10

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Targovax ASA (OSE: TRVX)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81




» top